HMGCR and fragile X syndrome: The involvement of cholesterol homeostasis dysfunctions in FXS is further supported by the evidence that HMGCR inhibitors partially correct symptoms in Fmr1 knock-out mice [47], suggesting a putative role of the MVA pathway in FXS manifestations, at least in animal models.